Mr. James Parsons reports
TRILLIUM ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARE UNITS AND SERIES II NON-VOTING CONVERTIBLE FIRST PREFERRED SHARE UNITS
Trillium Therapeutics Inc. has commenced a public offering of common share units of the company and Series II non-voting convertible first preferred share units of the company.
Each common share unit will consist of one common share of the company and one common share purchase warrant. Each Series II first preferred share unit will consist of one Series II non-voting convertible first preferred share and one Series II non-voting convertible first preferred share purchase warrant. The Series II first preferred share units are being offered to investors whose purchase of common share units in the offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99 per cent of the company's outstanding common shares following the consummation of the offering.
The company intends to use the net proceeds of the offering for: (i) continuing research and development activities of its SIRPaFc program; and (ii) working capital and general corporate purposes.
Cowen and Company LLC is acting as the sole book-running manager for the offering.
The offering is subject to market conditions, as well as a number of closing conditions, including Nasdaq Capital Market and Toronto Stock Exchange approvals, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. For the purposes of TSX approval, the company intends to rely on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
The offering is being made to purchasers outside of Canada pursuant to a United States registration statement on Form F-10, declared effective by the United States Securities and Exchange Commission on Jan. 8, 2018, and the company's existing Canadian short-form base shelf prospectus dated Jan. 5, 2018. The prospectus supplement relating to the offering (together with the base shelf prospectus and the registration statement, the "offering documents") will be filed with the securities commissions in the provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia in Canada, and with the SEC in the United States. The offering documents will contain important detailed information about the securities being offered. Before you invest, you should read the offering documents and the other documents the company has filed for more complete information about the company and the offering. Copies of the offering documents will be available for free by visiting the company's profiles on the SEDAR website maintained by the Canadian Securities Administrators or the SEC's website, as applicable. Alternatively, copies of the prospectus supplement will be available upon request by contacting Cowen and Company, care of (c/o) Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, N.Y., 11717, attention: Prospectus Department, or by e-mailing
About Trillium Therapeutics Inc.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.